PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Tjoapack announces major US expansion to improve its packaging and logistics capabilities

Tjoapack, a leading global contract packaging organization, has announced a significant strategic investment to expand its operational footprint in the U.S., strengthening its position as a trusted partner in pharmaceutical supply chain solutions.

The company  is developing a new 170,000-square-foot facility adjacent to its existing site in Clinton, Tennessee. The expansion will feature a comprehensive GMP suite, including packaging , labeling, cold chain and ambient storage capabilities to accommodate the rising client demand.

Scheduled for completion in early 2027, the new addition will support new high-speed packaging lines across a range of dosage forms, including oral solid dose (bottles and blisters) and injectable products (vials and auto-injectors), as well as various secondary packaging configurations.

 This expansion reflects the company’s ongoing commitment to investing in infrastructure that enhances service flexibility and addresses growing client demand across the pharmaceutical supply chain.

“This expansion marks a major step in our strategic goal to enhance our presence in the United States. As a crucial market with considerable growth opportunities, it allows us to serve our existing clients more effectively and attract new ones.” said Dexter Tjoa, CEO of Tjoapack.

“We’ve invested heavily in automating our core processes, not only within packaging lines but throughout our cross-company workflows with customers and material vendors. This allows us to reduce human error and enhance accuracy, speed, and flexibility, which ultimately benefits our clients..”

The Tjoapack US expansion builds on a series of enhancements to Tjoapack’s injectable packaging infrastructure over the past two years, including:

  • Automated vial packaging line: Commissioned and validated in May 2025, the fully integrated line features high-speed labeling, cartoning, and serialization capabilities, with an annual output of 15–20 million vials.

  • Semi-automated auto-injector packaging line: Commissioned and validated in September 2025, this line enables advanced labeling, cartoning, and serialization functionality.

  • Cold storage expansion: A 2.5x increase in capacity went online in October 2024, adding 160 pallet spaces for products requiring 2–8°C storage conditions.


About Tjoapack

Tjoapack is a global contract packaging organization specializing in pharmaceutical packaging solutions. With a strong focus on innovation and compliance, the company is committed to ensuring supply chain security and reliability for its clients.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026